-
Infection and Drug Resistance
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
Review
(2704) Views (733) Full article downloads
Authors: Lisa M Chirch, Roy T Steigbigel
Published Date April 2010
Volume 2010:3 Pages 15 - 23
DOI: http://dx.doi.org/10.2147/IDR.S9689
Lisa M Chirch, Roy T Steigbigel
Division of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA
Abstract: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs. Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients. Resistance to raltegravir is unusual given its recent availability, but resistance with identified viral mutation pathways in the integrase gene in patients receiving the drug does occur.
Keywords: raltegravir, integrase, human immunodeficiency virus, drug resistance
Readers of this article also read:
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Emerging agents to combat complicated and resistant infections: focus on ceftobiprole
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi
- Treatment of drug-resistant tuberculosis
- Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome
- High prevalence of multidrug-resistant MRSA in a tertiary care hospital of northern India




